@article{10.11648/j.ijmcr.20260501.11,
  author = {Tuan Ho and Yen Nguyen and Hoai-Thanh Lam},
  title = {Management of Stage IIA2 Cervical Cancer in the Third Trimester: A Case Report and Literature Review},
  journal = {International Journal of Medical Case Reports},
  volume = {5},
  number = {1},
  pages = {1-5},
  doi = {10.11648/j.ijmcr.20260501.11},
  url = {https://doi.org/10.11648/j.ijmcr.20260501.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijmcr.20260501.11},
  abstract = {Background: Cervical cancer remains one of the most frequently diagnosed gynecological malignancies during pregnancy, presenting a complex clinical dilemma when detected in the second trimester. The management of Stage IIA2 disease, defined by a bulky tumor size of ≥ 4cm without parametrial invasion, is particularly challenging. Standard interventions such as concurrent chemoradiation or immediate radical hysterectomy are incompatible with the preservation of the fetus. Consequently, Neoadjuvant Chemotherapy (NACT) has emerged as a therapeutic strategy to arrest tumor progression and delay delivery until fetal maturity is achieved. Case Presentation: We report the case of a 38-year-old multiparous female (G3P2) who was diagnosed with Stage IIA2 cervical cancer at 25 weeks of gestation. Following a multidisciplinary consultation, the patient was treated with NACT using a Paclitaxel and Carboplatin regimen to control the disease while allowing the fetus to mature. The patient completed four cycles of chemotherapy and was admitted to the obstetrics department at 37 weeks and 1 day of gestation. Pre-operative Magnetic Resonance Imaging (MRI) revealed a residual cervical mass measuring 3.1 x 4.1 x 2.8cm with invasion extending to the upper third of the vagina. Crucially, imaging confirmed the absence of parametrial invasion or pelvic lymphadenopathy. An elective Cesarean section was performed. The procedure resulted in the delivery of a healthy male neonate weighing 2700 grams, with Apgar scores of 8 at 1 minute and 9 at 5 minutes. The maternal postoperative course was uneventful, and the patient was subsequently transferred for definitive oncological management. Conclusion: This case illustrates that the administration of NACT is a viable and effective management strategy for Stage IIA2 cervical cancer diagnosed during the second trimester. This approach facilitates the prolongation of pregnancy to term, thereby minimizing neonatal morbidity associated with preterm birth, without compromising maternal oncological outcomes.},
 year = {2026}
}

Copy | Download

TY  - JOUR
T1  - Management of Stage IIA2 Cervical Cancer in the Third Trimester: A Case Report and Literature Review
AU  - Tuan Ho
AU  - Yen Nguyen
AU  - Hoai-Thanh Lam
Y1  - 2026/01/30
PY  - 2026
N1  - https://doi.org/10.11648/j.ijmcr.20260501.11
DO  - 10.11648/j.ijmcr.20260501.11
T2  - International Journal of Medical Case Reports
JF  - International Journal of Medical Case Reports
JO  - International Journal of Medical Case Reports
SP  - 1
EP  - 5
PB  - Science Publishing Group
SN  - 2994-7049
UR  - https://doi.org/10.11648/j.ijmcr.20260501.11
AB  - Background: Cervical cancer remains one of the most frequently diagnosed gynecological malignancies during pregnancy, presenting a complex clinical dilemma when detected in the second trimester. The management of Stage IIA2 disease, defined by a bulky tumor size of ≥ 4cm without parametrial invasion, is particularly challenging. Standard interventions such as concurrent chemoradiation or immediate radical hysterectomy are incompatible with the preservation of the fetus. Consequently, Neoadjuvant Chemotherapy (NACT) has emerged as a therapeutic strategy to arrest tumor progression and delay delivery until fetal maturity is achieved. Case Presentation: We report the case of a 38-year-old multiparous female (G3P2) who was diagnosed with Stage IIA2 cervical cancer at 25 weeks of gestation. Following a multidisciplinary consultation, the patient was treated with NACT using a Paclitaxel and Carboplatin regimen to control the disease while allowing the fetus to mature. The patient completed four cycles of chemotherapy and was admitted to the obstetrics department at 37 weeks and 1 day of gestation. Pre-operative Magnetic Resonance Imaging (MRI) revealed a residual cervical mass measuring 3.1 x 4.1 x 2.8cm with invasion extending to the upper third of the vagina. Crucially, imaging confirmed the absence of parametrial invasion or pelvic lymphadenopathy. An elective Cesarean section was performed. The procedure resulted in the delivery of a healthy male neonate weighing 2700 grams, with Apgar scores of 8 at 1 minute and 9 at 5 minutes. The maternal postoperative course was uneventful, and the patient was subsequently transferred for definitive oncological management. Conclusion: This case illustrates that the administration of NACT is a viable and effective management strategy for Stage IIA2 cervical cancer diagnosed during the second trimester. This approach facilitates the prolongation of pregnancy to term, thereby minimizing neonatal morbidity associated with preterm birth, without compromising maternal oncological outcomes.
VL  - 5
IS  - 1
ER  - 

Copy | Download